View Older Stories View More Recent Stories
-
Jnana Therapeutics to Participate in Upcoming Investor Conferences
-
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
-
Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies
-
Sortera Technologies Attends IAA Mobility 2023 Conference in Munich
-
Form SC 13D ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
-
Sortera Technologies Closes $30.5 Million in New Funding to Fully Commercialize Its State-of-the-Art Upcycling Facility
-
Inhibrx Inc. (INBX) Announces $200M Financing at $19.35/sh
-
Inhibrx Announces $200 Million Private Placement Financing
-
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
-
Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
-
Form SC 13G Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
ExcepGen Emerges From Stealth with New Funding for its Nucleic Acid Therapeutics Platform
-
Form SC 13G Gracell Biotechnologies Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G NEKTAR THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
-
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
-
Form SC 13G/A BELLUS Health Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Kinnate Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
-
Taysha Gene Therapies (TSHA) Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial
-
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results
-
Taysha Gene Therapies (TSHA) Announces $150M Financing
-
Taysha Gene Therapies Announces $150 Million Private Placement Financing
-
Form SC 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU
-
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
Gracell Biotechnologies (GRCL) Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline
-
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Latest Updates of 7 Viva's Portfolio Companies
-
UroGen Pharma (URGN) Announces $120 Million Private Placement of Ordinary Shares
-
UroGen Announces $120 Million Private Placement of Ordinary Shares
-
Form SC 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D
-
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
-
DTx Pharma announces acquisition by Novartis
-
Aerovate Therapeutics (AVTE) Appoints Habib Dable To Its Board
-
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
-
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
-
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
